0 CHECKOUT

Aerie Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

  • ID: 1999569
  • December 2011
  • 35 pages
  • Global Markets Direct

Aerie Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Aerie Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Aerie Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Aerie Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Aerie Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Aerie Pharmaceuticals, Inc. - Brief Aerie Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Aerie Pharmaceuticals, Inc. human therapeuti

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Aerie Pharmaceuticals, Inc. Snapshot
Aerie Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Aerie Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Aerie Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Aerie Pharmaceuticals, Inc. – Pipeline Products Glance
Aerie Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Aerie Pharmaceuticals, Inc. – Drug Profiles
AR-102
Product Description
Mechanism of Action
R&D Progress
AR-12286
Product Description
Mechanism of Action
R&D Progress
AR-12286 + Latanoprost
Product Description
Mechanism of Action
R&D Progress
Ocular Drug Insert Latanoprost
Product Description
Mec

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: This company profile will be emailed to you. The company profile is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: This company profile will be emailed to you. The company profile is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: This company profile will be emailed to you. The company profile is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Alexion Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Endo International Plc.
  • Essilor International S.A.